Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Pharmexa applies to begin phase I trial of HER-2 Protein AutoVac product

April 2, 2003

MediGene discontinues development of CVLP tumor vaccine

March 28, 2003

Protein Design Labs licenses SMART M195 antibody to Actinium

March 20, 2003

H3 Pharma licenses SC-1 from OncoMab

March 19, 2003

WX-G250 + low-dose IL-2 safe and active in progressive, metastatic RCC

March 18, 2003

GVAX enhances antitumor immunity in certain patients with advanced NSCLC

March 7, 2003

Aphton presents phase III results for G17DT to foreign regulatory authority

March 7, 2003

Aldara shows benefit in pivotal studies in actinic keratosis and basal cell carcinoma

March 5, 2003

Preliminary results from CpG-7909 proof-of-principle study announced

March 4, 2003

HuMax-CD20 kills rituximab-resistant tumor cells in preclinical studies

Feb. 20, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...